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ahe National Institutes of Health supports research
that informs clinical practice. To do this effectively,
it employs a variety of approaches to gather and
isseminate information on the safety and efficacy of med-
cal interventions. The accepted gold standard for genera-
ion of rigorous clinical evidence is the randomized clinical
rial. Randomized clinical trials (RCTs), however, have draw-
acks; they are generally expensive, have a long duration, are
ocused on a selected patient population, and their findings
ay be obsolete by the time the results are published. For some
linical research, a more practical option is the large clinical
egistry. Consequently, the National Heart, Lung, and Blood
nstitute (NHLBI) supports both approaches in its clinical
esearch programs directed at the prevention and treatment of
ardiovascular, lung, blood, and sleep disorders. However,
lthough a clinical registry is not a randomized clinical trial, it
hares the same goal: to translate efficiently and effectively
igorous clinical knowledge into improved care and clinical
utcomes for patients and public health. The capability of
egistries to reach this goal is evident in the products and
utcomes of an NHLBI-supported registry for patients with
echanical circulatory support devices. This registry, which is
escribed below, demonstrates its value and effectiveness by
rom the Division of Cardiovascular Sciences, National Heart, Lung, and Blood
nstitute, Bethesda, Maryland. The National Institutes of Health is the steward of
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ccepted May 17, 2010.ow it speeds the practical adoption of evidence into clinical
ractice, provides a means for post-market surveillance of
evices, and supports research on comparative effectiveness,
linical care, and patient management involving mechanical
irculatory support therapy.
Since the National Institutes of Health’s artificial heart
rogram was established in 1964, the NHLBI has funded a
eries of grants and contracts to develop mechanical circulatory
upport (MCS) devices, to improve related technology, and to
onduct clinical trials involving the devices. A growing number
f Food and Drug Administration (FDA)-approved MCS
evices have emerged that provide useful clinical therapies for
ate and end-stage heart failure patients (1). During this period,
HLBI has also funded other basic, translational, and clinical
esearch on heart failure and MCS, including circulatory
upport strategies for children (2).
The purpose of MCS devices is to augment or supplant
ailing myocardial performance (3,4). These devices can be
sed to provide necessary circulatory support until a donor
eart is available for transplantation or until a patient’s heart
ufficiently recovers. In these cases, the device is referred to
s a bridge-to-transplant or a bridge-to-recovery, respec-
ively. For chronic, severe heart failure patients who are not
ligible for heart transplantation and have little chance of
ecovery, MCS devices are used as permanent implants,
therwise known as destination therapy. The benefit of
estination therapy was first demonstrated in the NHLBI-
ponsored REMATCH (Randomized Evaluation of Me-
hanical Assistance for the Treatment of Congestive Heart
ailure) trial, conducted from 1998 through 2001. The trial
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August 24, 2010:738–40 Report on INTERMACS From the NHLBIesults clearly demonstrated a clinically meaningful survival
enefit and an improved quality of life with ventricular assist
evice therapy in end-stage heart failure patients as com-
ared with those receiving optimal medical management
5). Despite the benefits, the mortality and adverse events
ssociated with device use in the REMATCH trial high-
ighted the need to understand the implications of the therapy
or the intended patient population and to monitor device
erformance and clinical outcomes closely over time. As device
echnology evolves, improvements are expected to reduce the
isk of adverse events and to improve quality of life in these
atients and enhance the potential for recovery in others (6,7).
Because of the nature of MCS devices and the desire to
mprove outcomes, a registry for patients who receive MCS
evices is well justified. The need for such a registry was
nvisioned almost 2 decades ago when the Institute of
edicine (IOM) recommended that NHLBI maintain a
egistry of MCS device recipients as a “routine aspect of this
are” (8). The IOM recognized this need based on patients’
ependence on the devices and the uncertainty of the
ong-term benefits and drawbacks. The immediate need for
uch a registry was realized in 2003 by the Centers for
edicare and Medicaid Services (CMS). At that time, in
heir decision to cover destination therapy, the CMS re-
uired that any patient who received a ventricular assist
evice as destination therapy should be entered into a
ationally audited registry.
With the clear and publically disclosed need for a MCS
evice registry, NHLBI issued a Request for Proposals in
004 for an Interagency Registry of Mechanical Circulatory
upport for End-Stage Heart Failure. The overall expecta-
ion of the registry was that it would help to advance the
nderstanding and application of MCS to improve the
ortality, morbidity, and health status in patients with
dvanced heart failure. The result of the solicitation was a
ompetitive contract awarded inMay 2005 to the University of
labama at Birmingham (9) to establish and manage what has
ecome known as the INTERMACS (Interagency Registry
or Mechanically Assisted Circulatory Support). Since the
egistry’s launch in June 2006, INTERMACS has become the
ational registry of patients receiving FDA-approved durable
CS devices to treat advanced heart failure. Specific objectives
f INTERMACS include: 1) collecting and disseminating
uality data that help to improve patient selection and clinical
anagement of patients receiving MCS devices; 2) advancing
he development and regulation of existing and next-
eneration devices; and 3) enabling research into heart failure
nd recovery (9,10). As of January 1, 2010, INTERMACS
ad more than 100 participating hospitals, more than 2,000
atients entered into the registry, and more than 90% data
eporting and completeness of forms (11).
INTERMACS resulted from the cooperative efforts of
CS clinicians, scientists, manufacturers, and federal partners.
he 3 federal partners involved are: 1) the NHLBI, which
unds and oversees the registry; 2) the FDA, which regulates
CS devices; and 3) the CMS, which reimburses for MCS Hevice use. The stake holders
orked cooperatively to develop
tandard definitions, data ele-
ents, and data collection time
oints through an iterative process
ver the first year of the contract.
hese processes and standards
ere necessary to assure accurate,
imely, and comprehensive data
ollection, which began in June
006. As a result, INTERMACS
as become a rigorous tool that is
ell positioned to help develop
uidelines and improve clinical
ractice, because it incorporates many elements of RCTs.
xamples include: 1) well-defined inclusion and exclusion
riteria; 2) precise adverse event definitions; 3) complete data
ollection and follow-up; 4) adjudication of outcomes and
vents; 5) planned statistical analyses; 6) training for investiga-
ors and coordinators; and 7) committee oversight, such as that
y the Observational Study Monitoring Board established by
he NHLBI.
Because INTERMACS is a registry, it can facilitate the
ranslation of evidence into clinical practice more quickly than
CTs can (12). Although RCTs have the benefit of an
xperimental design, they are restricted by the initial inclusion
nd exclusion criteria, definitions, and available therapies. They
re also often difficult to begin and manage, long in duration,
nd focused on a highly selected patient population that may
ot reflect clinicians’ daily practice. Dissemination of data and
ndings from an RCT also are usually constrained until well
fter the trial is completed. Registries like INTERMACS are
uch more flexible and allow for more timely data dissemina-
ion. Reports generated from the analyzed audited INTER-
ACS data are provided to the collaborating clinical sites,
ederal partners, industry collaborators, and principal investi-
ators on a quarterly basis. Site-specific data are used by
articipating hospitals to meet joint commission hospital com-
liance quality reporting requirements and to drive improve-
ents in hospital performance. Device-related serious adverse
vents now also are reported directly to the FDA by INTER-
ACS. This, in turn, has obviated the need for participating
ospitals to report device-related events, has expedited receipt
y the FDA, and has helped to fulfill the FDA requirements
or reporting of these data.
The rapid dissemination of data from INTERMACS has
acilitated the recognition of real-time trends in medical
ractice that involve MCS. For example, during the first 3
ears of data collection, INTERMACS documented im-
ortant trends in device characteristics and use and in
atient outcomes (13,14). When the registry was launched,
he vast majority of devices being implanted were large,
ositive-displacement, pulsatile devices developed in the
970s and 1980s, such as the Heartmate XVE (Thoratec
orp., Pleasanton, California) and NovaCor PC (World
Abbreviations
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CMS  Centers for Medicare
and Medicaid Services
FDA  Food and Drug
Administration
IOM  Institute of Medicine
MCS  mechanical
circulatory support
NHLBI  National Heart,
Lung, and Blood Institute
RCT  randomized clinical
trialeart Corp., Oakland, California). INTERMACS captured
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Report on INTERMACS From the NHLBI August 24, 2010:738–40he trend toward implantation of smaller continuous flow
umps developed in the 1990s and early 2000s and recently
pproved by the FDA (Table 1). In addition, INTERMACS
as shown that the therapeutic goals articulated at the time of
mplantation of durable pumps can evolve (15). Instead of a
trict differentiation between device implantation as either a
ridge-to-transplant or destination therapy, the data suggest
hat some destination therapy patients, who initially were
etermined to be unsuitable for transplantation, may resolve
hysiologic or psychosocial barriers while receiving MCS and
ay become suitable for transplantation. Similarly, in patients
reated with a bridge-to-transplant strategy, conditions or
omplications may develop that make transplantation an un-
uitable option (16).
INTERMACS also has been designed to stratify patients
hat MCS therapy targets by defining subsets within the
ew York Heart Association functional class III and IV
ategories. These have been termed INTERMACS patient
rofiles and include: profile 1, Critical Cardiogenic Shock;
rofile 2, Progressive Decline on Inotropic Support; profile
, Stable but Inotrope Dependent; profile 4, Resting Symp-
oms Home on Oral Therapy; and profiles 5, 6, and 7,
ontinuum of Class IV Patients with Restricted Activity
nd with Little Fluid Overload (17). After the first year of
ollection, INTERMACS data have revealed that almost
2% of patients receiving devices are in the highest severity
rofile. Over the last 2 years, the registry has documented a
ecrease in the proportion of profile 1 patients to 28%, with
shift toward profiles 2 through 7. INTERMACS also has
ocumented that profiles 1 and 2 account for a high
roportion of the early mortality. Thus, INTERMACS has
een able to document a significant change in practice
uring a short period, as clinicians now seek to improve the
linical status to better profiles before implantation (18).
INTERMACS demonstrates how a well-designed regis-
ry can facilitate the adoption of evidence into clinical
ractice. The vision beyond INTERMACS is for the
egistry to become a definitive resource to inform patient
election, to advance scientific investigation and device
evelopment, to guide clinical practice, to contribute to the
able 1 Distribution of Implanted Ventricular Assist Devices and
otal Artificial Hearts During the First 3 Years of INTERMACS
Year
Left-Side Pumps (LVADs and Bi-VADS)
Total
Artificial
HeartsPulsatile Pumps
Continuous
Flow Pumps
n % n % n %
ear 1 (7/2006–6/2007) 291 96.0% 2 0.7% 10 3.3%
ear 2 (7/2007–6/2008) 332 71.1% 113 24.2% 22 4.7%
ear 3 (7/2008–3/2009) 111 17.6% 502 79.4% 19 3.0%
mplant dates: June 23, 2006 to March 31, 2009. Number of patients: 1,402. Note: Included in this
able are left ventricular assist devices (LVADs), biventricular (left and right) assist devices
Bi-VADS), and total artificial hearts manufactured by Abiomed, Inc., Micromed Technology, Inc.,
ynCardiaSystems, Inc., and Thoratec Corporation. Eighteen isolated right ventricular assist
evices have been removed from this table.
INTERMACS  Interagency Registry for Mechanically Assisted Circulatory Support.dvancement of a technology, and ultimately to improve the yreatment of advanced heart failure. On a larger scale,
NTERMACS may serve as a model for developing and
sing registries more commonly to facilitate, improve, and
ccelerate the adoption of other therapies.
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